Service Agreement Icon

Dublin, Ireland, April 3, 2020 – ICON plc, (NASDAQ: ICLR), a global leader in drug and equipment development and marketing services for the pharmaceutical, biotech and medical industries, today announced that it has signed a three-year contract with Pfizer Inc. (NYSE: PFE). Under the agreement, Pfizer has the right to extend the term for up to two more years. Financial details of the agreement were not disclosed. The agreement builds on the existing relationship between companies, under which ICON provides global expertise in the design, implementation, management and execution of clinical trials. ICON plc is a global provider of outsourced drug development and marketing services for pharmaceutical, biotechnology, medical device and healthcare organizations. The company specializes in strategic development, management and analysis of programs that support clinical development, from composite selection to Phase I-IV clinical trials. Based in Dublin, Ireland, ICON currently operates at 97 sites in 40 countries and employs approximately 14,650 people as of 31 December 2019. For more information, see www.iconplc.com. This press release contains forward-looking statements. These statements are based on management`s current expectations and information, including current economic and sectoral conditions.

These statements are not guarantees for future performance or actual results, and actual results, developments and business decisions may differ from those mentioned in this press release. Forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated in the statements, including, but not limited to, the ability to enter into new contracts, maintaining customer relationships, managing the opening of new offices and the provision of new services, the integration of new business combinations and acquisitions, as well as economic and global market conditions and other risks and uncertainties, detailed from time to time in ICON`s reports, all of which are difficult to predict. For these reasons, you should not rely too much on these forward-looking statements to make investment decisions. The purpose of the word “expected” and the variations in such words and expressions is to identify forward-looking statements. Forward-looking statements are made only from the date of filing and we undertake no obligation to publicly update any forward-looking statements, whether based on new information, future events or otherwise. For more information on the risks and uncertainties associated with these forward-looking statements, see the SEC reports submitted by ICON, including Form 20-F, F-1, S-8 and F-3, available on the SEC`s website at www.sec.gov. View source version on businesswire.com: www.businesswire.com/news/home/20160610005206/en/ . Steve Cutler, CEO of ICON, said: “Continuing to develop ICON`s long-standing relationship with Pfizer is a clear recognition of our expertise and expertise in partnering with Pfizer in drug development and marketing. We look forward to continuing our close collaboration with Pfizer to advance its pipeline and bring further innovations to the drug development process. ICONInvestor Relations1-888-381-7923orBrendan BrennanChief Financial Officer 353 -1-291-2000orSimon HolmesEVP Investor Relations and Corporate Development 353 -1-291-2000 . .

. Source: ICON plc Contact: Investor Relations `1888 381 7923` or Jonathan Curtain Vice President Corporate Finance and Investor Relations `353 1 291 2000.